PDS Biotechnology Corp
PDSB Nasdaq
SEC CIK 1472091
Follow PDS Biotechnology
Weekly email: filings, results
Net income
−$7.6M
+15.4% vs same quarter last year
EPS, diluted
−$0.11
+42.1% vs same quarter last year
Operating cash flow
−$8.2M
−39% vs same quarter last year
Operating income
−$5.9M
+27.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$34.5M |
| FY24 | −$37.6M |
| FY23 | −$42.9M |
| FY22 | −$40.9M |
| FY21 | −$16.9M |
| FY20 | −$14.8M |
| FY19 | −$7M |
| FY18 | - |
| FY17 | −$50.9M |
| FY16 | −$38.8M |
| FY15 | −$28.1M |
| FY14 | −$12.2M |
| FY13 | −$6.9M |
| FY12 | - |
| FY11 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$27.8M |
| FY24 | −$35.1M |
| FY23 | −$33.6M |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | −$1.6M |
| FY17 | −$40.9M |
| FY16 | −$32.9M |
| FY15 | −$23.1M |
| FY14 | −$10.6M |
| FY13 | −$8.2M |
| FY12 | - |
| FY11 | - |